GSK3-beta Protein is a protein involved in key cellular signaling pathways relevant to neurodegenerative diseases. This page provides comprehensive information about its structure, normal biological function, and role in disease pathogenesis.
GSK3-beta Protein participates in critical cellular processes that, when dysregulated, contribute to neurodegeneration. Understanding this protein's function is essential for developing therapeutic interventions for Alzheimer's disease, Parkinson's disease, and related conditions.
| GSK3-beta Protein | |
|---|---|
| Protein Name | GSK3-beta |
| Gene | [GSK3B](/genes/gsk3b) |
| UniProt ID | P49841 |
| PDB Structure | 1H8F, 1PYX, 4ITG |
| Molecular Weight | 46 kDa |
| Subcellular Localization | Cytoplasm, Nucleus, Mitochondria, Synapses |
| Protein Family | GSK3 family (serine/threonine protein kinase) |
GSK3-beta is a serine/threonine kinase with a catalytic domain that binds ATP and substrates. The protein contains an N-terminal regulatory region with key phosphorylation sites (Ser9 for inactivation) and a kinase domain. GSK3-beta forms complexes with various proteins that modulate its activity and substrate specificity.
GSK3-beta is a constitutively active kinase that phosphorylates over 100 substrates. It regulates glycogen metabolism, gene expression, protein synthesis, cell cycle, and neuronal function. In the Wnt pathway, GSK3-beta phosphorylates beta-catenin, targeting it for degradation. In neurons, GSK3-beta regulates synaptic plasticity, microtubule dynamics, and neuronal survival through phosphorylation of tau, synapsin, and transcription factors.
GSK3-beta is centrally implicated in AD pathogenesis: (1) it hyperphosphorylates tau at multiple sites, promoting NFT formation; (2) it regulates APP processing and Aβ generation; (3) activity is elevated in AD brains. In PD, GSK3-beta contributes to dopaminergic neuron degeneration through effects on mitochondrial function, autophagy, and alpha-synuclein aggregation.
GSK3-beta inhibitors are extensively studied for AD and PD. Lithium directly inhibits GSK3-beta and has shown benefits in AD models. Other inhibitors include Tideglusib, Valproic acid, and small molecules in development. Challenges include achieving brain penetration and avoiding pleiotropic effects.